Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
98 EUR | -1.01% | -.--% | +2.08% |
10/05 | Cipla Open to Partner With Eli Lilly to Market Obesity Drugs in India | MT |
10/05 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
Sales 2024 * | 42.81B 39.75B 3,574B | Sales 2025 * | 52.47B 48.72B 4,381B | Capitalization | 684B 635B 57,133B |
---|---|---|---|---|---|
Net income 2024 * | 11.93B 11.08B 996B | Net income 2025 * | 16.55B 15.37B 1,382B | EV / Sales 2024 * | 16.5 x |
Net Debt 2024 * | 19.98B 18.55B 1,668B | Net Debt 2025 * | 15.29B 14.19B 1,276B | EV / Sales 2025 * | 13.3 x |
P/E ratio 2024 * |
56.8
x | P/E ratio 2025 * |
40.9
x | Employees | - |
Yield 2024 * |
0.68% | Yield 2025 * |
0.79% | Free-Float | 99.8% |
Latest transcript on Eli Lilly and Company
1 day | -1.01% |
Managers | Title | Age | Since |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/96/01 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 63 | 25/21/25 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 01/09/01 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/05/01 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock